Join Dr. Richard T. Kloos, Executive Medical Director at Veracyte, as he explores breakthrough insights from over 50,000 consecutive Bethesda III-VI samples analyzed using the Afirma Genomic Sequencing Classifier (GSC). Originally presented at the 2021 American Thyroid Association Annual Meeting, this symposium highlights the clinical impact of molecular diagnostics in thyroid nodule evaluation and patient care.
Dr. Kloos reviews key findings from a landmark publication by Hu et al., showcasing how the data are shaping the future of personalized thyroid care and highlighting the evolution of Afirma GSC as a comprehensive solution in patient thyroid nodule management. From thyroid nodule treatment and molecular testing to FDA-approved RET inhibitors and the power of RNA expression, Dr. Kloos demonstrates the value of genomic data in predicting tumor behavior and informing clinical workflows.
Learn more about integrating advanced molecular tools into routine patient management for improved patient outcomes and how Afirma GSC by Veracyte are helping lead the way in offering a seamless workflow for thyroid nodule management.
Working together with the cancer research community, our mission is to advance thyroid cancer care with exceptional genomic testing for personalized treatment planning.
Key topics
- 0:00 – Introduction
- 1:20 – Evolution of the Afirma GSC
- 5:00 – Thyroid Nodule Treatment
- 6:00 – Molecular Testing
- 13:40 – Value of Genomic Findings
- 14:30 – FDA Approved RET Inhibitors
- 17:20 – The Power of RNA Expression
- 20:00 – Correlation of Tumor Behavior
- 22:40 – Afirma GSC & Xpression Atlas
- 27:00 – Clinical Workflow With Molecular Testing
Speakers
Richard T. Kloos, M.D.
Veracyte
Tags
On Demand
Afirma Thyroid